Trial Profile
Gemcitabine and Nab-Paclitaxel Combined With the Oral Irreversible ErbB Family Blocker Afatinib in Patients With Metastatic Pancreatic Cancer: A Phase Ib Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms AFFECT
- 09 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 01 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.